These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 15334176)

  • 1. Molecule of the month. PA-457.
    Drug News Perspect; 2004 May; 17(4):283. PubMed ID: 15334176
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor.
    Temesgen Z; Feinberg JE
    Curr Opin Investig Drugs; 2006 Aug; 7(8):759-65. PubMed ID: 16955688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maturation inhibitors as new antiretroviral agents.
    Richards J; McCallister S
    J HIV Ther; 2008 Dec; 13(4):79-82. PubMed ID: 19418657
    [No Abstract]   [Full Text] [Related]  

  • 4. New drugs.
    Pozniak A
    J HIV Ther; 2008 Jun; 13(2):27-33. PubMed ID: 18953271
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase 1 clinical data on first-in-class HIV-1 maturation inhibitor, PA-457.
    S Afr Med J; 2004 Sep; 94(9):739. PubMed ID: 15487834
    [No Abstract]   [Full Text] [Related]  

  • 6. Maturation inhibitors: a new therapeutic class targets the virus structure.
    Salzwedel K; Martin DE; Sakalian M
    AIDS Rev; 2007; 9(3):162-72. PubMed ID: 17982941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.
    Smith PF; Ogundele A; Forrest A; Wilton J; Salzwedel K; Doto J; Allaway GP; Martin DE
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3574-81. PubMed ID: 17638699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study may point way forward for bevirimat.
    Proj Inf Perspect; 2008 Dec; (47):11. PubMed ID: 19227562
    [No Abstract]   [Full Text] [Related]  

  • 9. PA-457, new kind of antiretroviral: ten-day clinical trial results.
    James JS
    AIDS Treat News; 2005 Aug; (414):7-8. PubMed ID: 16206398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients.
    Malet I; Wirden M; Derache A; Simon A; Katlama C; Calvez V; Marcelin AG
    AIDS; 2007 Apr; 21(7):871-3. PubMed ID: 17415044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of activity of the HIV-1 maturation inhibitor PA-457.
    Li F; Zoumplis D; Matallana C; Kilgore NR; Reddick M; Yunus AS; Adamson CS; Salzwedel K; Martin DE; Allaway GP; Freed EO; Wild CT
    Virology; 2006 Dec 5-20; 356(1-2):217-24. PubMed ID: 16930665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prediction of the efficacy of bevirimat used for the treatment of HIV infection in Russia].
    Kazennova EV; Vasil'ev AV; Bobkova MR
    Vopr Virusol; 2010; 55(3):37-41. PubMed ID: 20608080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promising phase I results against new HIV target.
    Whelan J
    Drug Discov Today; 2004 Oct; 9(19):823. PubMed ID: 15381130
    [No Abstract]   [Full Text] [Related]  

  • 14. The need for novel targets and approaches to HIV therapy.
    Martinez LJ
    Res Initiat Treat Action; 2002; 8(1):23-5. PubMed ID: 12489523
    [No Abstract]   [Full Text] [Related]  

  • 15. A new assault on HIV.
    Stix G
    Sci Am; 2006 Jun; 294(6):76-9. PubMed ID: 16711363
    [No Abstract]   [Full Text] [Related]  

  • 16. Revisiting the concept of a genetic barrier to resistance.
    Rusconi S
    J HIV Ther; 2006 Dec; 11(4):81-3. PubMed ID: 17578211
    [No Abstract]   [Full Text] [Related]  

  • 17. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.
    Martin DE; Salzwedel K; Allaway GP
    Antivir Chem Chemother; 2008; 19(3):107-13. PubMed ID: 19024627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 3-O-(3',3'-dimethylsuccinyl) derivative of betulinic acid (DSB) inhibits the assembly of virus-like particles in HIV-1 Gag precursor-expressing cells.
    DaFonseca S; Blommaert A; Coric P; Hong SS; Bouaziz S; Boulanger P
    Antivir Ther; 2007; 12(8):1185-203. PubMed ID: 18240859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The maturation inhibitor bevirimat (PA-457) can be active in patients carrying HIV type-1 non-B subtypes and recombinants.
    Yebra G; Holguín A
    Antivir Ther; 2008; 13(8):1083-5. PubMed ID: 19195334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can the further clinical development of bevirimat be justified?
    Wainberg MA; Albert J
    AIDS; 2010 Mar; 24(5):773-4. PubMed ID: 20154583
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.